Lymphoma Clinical Trials

Showing 1701-1720 of 3,379 trials

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)

NCT04974996

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, and identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combination therapy.

Diffuse Large B-Cell Lymphoma

ADC Therapeutics S.A.Started Feb 2022

Cleveland, Ohio, United States

UNKNOWNPhase 1/2

Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT

NCT04764513

This study investigates the infusion safety and potential curative properties of ex-vivo expanded γδ T cells obtained from the same donor for patients who have hematological malignancies and have accepted allogeneic hematopoietic stem cell transplantation.

Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic Syndromes+1 more

Chinese PLA General Hospital20 participantsStarted Sep 2021

Beijing, China

UNKNOWNPhase 1

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

NCT05003141

Product: PSB202 is a novel biological entity consisting of two engineered monoclonal antibodies, an Fc-enhanced humanized type II anti-CD20 IgG1 (PSB102) and a humanized anti-CD37 IgG1 (PSB107), that target B-cells. PSB202 is manufactured to work as a single product with the two components of PSB202 enabling a distinct dual target-specific antibody directed cell killing of B-cells. Study: Multi-center-, International Phase 1a/1b (Escalation/Expansion) study in patients with indolent-, relapsed-, B-cell malignancies. The Phase 1a (Dose Escalation) part of study follows a 3+3 design.

Follicular LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWaldenstrom Macroglobulinemia+5 more

Qilu Puget Sound Biotherapeutics (dba Sound Biologics)110 participantsStarted Nov 2021

Louisville, Kentucky, United States • New York, New York, United States • East Melbourne, Victoria, Australia +2 more locations

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)

Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Related Searches

Usefulness of Gadovist-enhanced FLAIR Imaging

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia

Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma

Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects

Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma

Treatment of Primary CNS Lymphoma ( FTD )

Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

Prognostic Value Of Lymphocyte Count and Lymphocyte/ Monocyte Ratio in Patients With Hodgkin's Lymphoma

Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma

Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Mathematic Modeling at Micro and Macroscopic Level of Primary Central Nervous System Lymphomas (PCNSL)

A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat